Valproate eases symptoms of SMA

[Guest guest]

<http://mednews.wustl.edu/news/page/normal/7351.html>

Epilepsy drug eases symptoms of inherited disorder that weakens muscles

Media Assistance:

Purdy

Senior Medical Sciences Writer

purdym@...

(314) 286-0122

By Purdy

June 23, 2006 -- An epilepsy drug that has been on the market for

decades can ease the symptoms of adult sufferers with a genetic disorder

that seriously weakens muscles.

Scientists at Washington University School of Medicine in St. Louis

retrospectively reviewed results from off-label use of the drug

valproate to treat seven adult spinal muscular atrophy (SMA) patients.

Clinicians offered the drug to patients on the basis of research

conducted elsewhere that showed the drug increased levels of a key

protein in cell cultures.

" The treatment has been fairly successful, " says lead author Chris

Weihl, M.D., Ph.D., a postdoctoral fellow in neurology. " The drug

appeared to be well-tolerated and increased the strength of the patients

who took it. "

The study, now available online, will appear in the August 8 issue of

Neurology.

Weihl notes that a larger, prospective trial is needed to firmly

establish valproate as a treatment of choice for sufferers of this type

of SMA.

Such trials are already underway elsewhere in pediatric patients who

suffer from a different type of SMA that begins earlier in life. Weihl

and his colleagues are concerned that valproate may not work as well in

those patients. They wanted to make sure that researchers did not

discard the possibility that valproate could help older sufferers even

if the trials in pediatric patients went poorly.

" Based on what we know of the unique genetics of this disease, there was

reason to think that this drug could be more helpful to patients who

develop SMA later in life, " Weihl says.

Patients with all forms of SMA, which affects approximately one of every

6,000 babies born in the U.S., are missing the SMN1 gene, which makes

the survival motor neuron (SMN) protein. This progressively weakens the

muscles, leading to difficulty in walking, eating, clearing the air

passageway, and other essential functions.

Based on when the symptoms of SMA first manifest, physicians divide SMA

into four subtypes. SMA I, for example, strikes very young children,

causing weakness in the womb, preventing children from ever walking and

typically resulting in death at an early age. Patients with SMA IV, in

contrast, don't develop weakness until adulthood. The seven patients

studied were either SMA III or SMA IV, and ranged in age from 17 to 54.

Differences in age of SMA onset have been directly linked to a second

human gene that also makes the SMN protein. That gene, SMN2, isn't as

efficient at making the SMN protein as SMN1. Patients who develop SMA

early in life have only one copy of the SMN2 gene in their DNA, leaving

them with very low levels of the SMN protein. Patients who get the

disorder later in life have more copies of the SMN2 gene, increasing the

amount of SMN protein made in their cells and delaying onset.

" Because we have learned so much about SMA over the last decade, there's

been a big push at NIH to cure this disease, " Weihl says. " The search

has been on to find a treatment that can increase the amount of SMN2

protein synthesized by SMN2 genes. This rapid bench-to-bedside

transition for valproate is a good example of the kind of progress that

is encouraged both by NIH and the University's Biomed 21 initiative. "

In addition to its use as an epilepsy treatment, valproate, which is

sold under the brand name Depakote, has been used to treat bipolar

disorder, migraine headaches and other neurological conditions. The

drug's effects include increasing the number of times protein-building

instructions are read from genes, which is the first step in creating

copies of proteins like SMN.

As patients took the drug, clinicians regularly gave them a series of

strength tests. When Weihl reviewed the data from those tests, he found

patient strength had increased significantly over the course of eight to

15 months of treatment with the drug.

According to Weihl, simply increasing the strength of an SMA patient's

cough might enable them to clear their lungs better and reduce incidence

of pneumonia, the most common killer of patients with SMA III and IV.

Valproate's side effects can include weight gain, hair loss and acne.

One patient stopped taking the drug because she was concerned about

weight gain.

" Adding weight can be a problem in patients who are already weak, and

it's certainly a legitimate reason to stop taking the drug, but overall

we didn't see significant weight gains in patients taking the drug, "

Weihl says.

Weihl and his colleagues are continuing to follow the seven patients

reviewed in the study, who are still taking a daily maintenance dose of

the drug.

Weihl CC, Connolly AM and Pestronk A. Valproate may improve strength and

function in patients with type III/IV spinal muscle atrophy. Neurology,

August 8, 2006.

Washington University School of Medicine's full-time and volunteer

faculty physicians also are the medical staff of -Jewish and St.

Louis Children's hospitals. The School of Medicine is one of the leading

medical research, teaching and patient care institutions in the nation,

currently ranked fourth in the nation by U.S. News & World Report.

Through its affiliations with -Jewish and St. Louis Children's

hospitals, the School of Medicine is linked to BJC HealthCare.